Apogee Therapeutics Inc (APGE) 2025 Conference Transcript

Apogee Therapeutics Inc (APGE) 2025 Conference May 13, 2025 04:40 PM ET Speaker0 Sixteen week endpoint for atopic derm. Here, we aim to show that with roughly half the number of doses during the induction period and then three months or less frequent dosing and maintenance, we can again transform this market. Beyond atopic derm, we're also planning phase two b in asthma and a that will start later this year and a phase two in EOE, which would start next year. This will give us kind of phase two dose optimiz ...